Biotechnology

Pharmaceuticals Startups Pharmaceutical Industry Drug Development Genetic Testing Pharmaceutical Companies Acquisitions Life Sciences Clinical Trials Gene Therapies

4 ARTICLES

4w ago

Nektar Therapeutics’ Rezpegaldesleukin Trial Success Sends Shares Up 150%

The FDA granted Fast Track status in February after strong midstage data highlighted its potential to address unmet needs in moderate-to-severe atopic dermatitis.

4 ARTICLES

last mo.

Lotte Biologics Wins Manufacturing Deal to Produce Ottimo Pharma’s Jankistomig

8 ARTICLES

last mo.

Sarepta Halts Elevidys Shipments for Non-Ambulatory Patients After Second Fatal Liver Failure

12 ARTICLES

last mo.

Samsung Biologics Announces Spin-Off of Biosimilar Unit to Form Samsung Epis Holdings

3 ARTICLES

2mo ago

Novo Nordisk Partners with Septerna in $2.2 Billion Deal for Oral Obesity Therapies

7 ARTICLES

2mo ago

Biontech Reports Q1 Loss as Focus Shifts to mRNA Cancer Therapies

3 ARTICLES

3mo ago

Lotte Biologics Secures First ADC Manufacturing Deal, Launches Full-Scale Operations

3 ARTICLES

4mo ago

Biogen Announces Move to New Headquarters in Kendall Common

3 ARTICLES

4mo ago

Cargo Therapeutics Ceases Operations Following Clinical and Financial Setbacks

3 ARTICLES

4mo ago

AstraZeneca Acquires Belgian Biotech EsoBiotec in $1 Billion Deal

4 ARTICLES

4mo ago

Roche and Zealand Partner in $5.3 Billion Deal for Obesity Drug Development

3 ARTICLES

5mo ago

23andMe Explores Strategic Options as Financial Struggles Deepen

3 ARTICLES

6mo ago

Moderna Secures $590M U.S. Grant to Advance Bird Flu Vaccine Development

5 ARTICLES

6mo ago

Neumora’s Depression Drug Fails to Meet Goals in Key Phase 3 Trial

Particle.news

Biotechnology

Nektar Therapeutics’ Rezpegaldesleukin Trial Success Sends Shares Up 150%

Lotte Biologics Wins Manufacturing Deal to Produce Ottimo Pharma’s Jankistomig

Sarepta Halts Elevidys Shipments for Non-Ambulatory Patients After Second Fatal Liver Failure

Wojcicki’s Nonprofit Tops Regeneron With $305M Bid for 23andMe

BioNTech Moves to Complete $1.25 Billion Curevac Takeover

BioNTech to Acquire CureVac for $1.25 Billion to Drive mRNA Cancer Therapy

BioNTech to Acquire CureVac for $1.25 Billion

Zydus Lifesciences to Acquire Agenus’ California Biologics Facilities

Biocon Secures CDSCO Approval for Generic Liraglutide

Samsung Biologics Announces Spin-Off of Biosimilar Unit to Form Samsung Epis Holdings

Never miss stories about

Biotechnology

Novo Nordisk Partners with Septerna in $2.2 Billion Deal for Oral Obesity Therapies

Biontech Reports Q1 Loss as Focus Shifts to mRNA Cancer Therapies

Lotte Biologics Secures First ADC Manufacturing Deal, Launches Full-Scale Operations

Biogen Announces Move to New Headquarters in Kendall Common

Cargo Therapeutics Ceases Operations Following Clinical and Financial Setbacks

AstraZeneca Acquires Belgian Biotech EsoBiotec in $1 Billion Deal

Roche and Zealand Partner in $5.3 Billion Deal for Obesity Drug Development

23andMe Explores Strategic Options as Financial Struggles Deepen

Moderna Secures $590M U.S. Grant to Advance Bird Flu Vaccine Development

Neumora’s Depression Drug Fails to Meet Goals in Key Phase 3 Trial

Never miss stories about

Biotechnology